Objective: To determine the effect on survival after transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).
Design: Longitudinal cohort study.
Place And Duration Of Study: Radiology Department, The Aga Khan University Hospital, Stadium Road, Karachi, from December 1997 to September 2005.
Patients And Methods: Patients undergoing TACE procedure for HCC were prospectively followed. Fortythree patients were enrolled from December 1997 to March 2003 in the study and subjected to chemoembolization therapy. Eight out of 43 patients were excluded from the study, who lost to follow-up. All the patients were followed till their death. Median and mean survival were calculated.
Results: The median survival of these 35 patients was 410 days (13.6 months), with 95% confidence interval (236 days lower bound and 536 days upper bound). Mean survival time was 603 days (20.1 months) with 95% confidence interval (394 days lower bound and 812 days upper bound). There was significant difference in mean survival time (in days) by Child s Pugh class (chi(2) = 12.384; df=2, p-value=0.002).
Conclusion: The study showed that TACE is an effective palliative treatment. TACE increases the median survival time.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial.
Cancer Commun (Lond)
January 2025
Department of Respiratory and Critical Care Medicine, Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, P. R. China.
Background: The prognosis for non-small cell lung cancer (NSCLC) patients treated with standard platinum-based chemotherapy was suboptimal, with safety concerns. Following encouraging results from a preliminary phase I study, this phase II trial investigated the efficacy and safety of first-line sintilimab and anlotinib in metastatic NSCLC.
Methods: In this open-label, randomized controlled trial (NCT04124731), metastatic NSCLC without epithelial growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or proto-oncogene tyrosine-protein kinase ROS (ROS1) mutations, and previous treatments for metastatic disease were enrolled.
Outcomes and Prognostic Factors in Patients With Untreated Head and Neck Squamous Cell Carcinoma.
Cureus
January 2025
Department of Otorhinolaryngology, Jikei University Kashiwa Hospital, Kashiwa, JPN.
Objectives: Although several studies have reported the treatment prognosis in squamous cell carcinoma of the head and neck, few studies exist on the prognosis and mortality-related risk factors in untreated cases. This study aimed to determine the outcomes of patients with head and neck squamous cell carcinoma who underwent no treatment and investigate the associated factors.
Methods: This retrospective, single-institution study initially included 718 patients with head and neck cancer who visited our hospital between January 2015 and December 2021; 43 untreated patients were included in the final analysis.
Abdominal myosteatosis measured with computed tomography predicts poor outcomes in patients with glioblastoma.
Neurooncol Adv
November 2024
Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, Saint Louis, Missouri, USA.
Background: Alterations in cellular metabolism affect cancer survival and can manifest in metrics of body composition. We investigated the effects of various body composition metrics on survival in patients with glioblastoma (GBM).
Methods: We retrospectively analyzed patients who had an abdominal and pelvic computed tomography (CT) scan performed within 1 month of diagnosis of GBM (178 participants, 102 males, 76 females, median age: 62.
Device Exchange to HeartMate 3 LVAD: Impact of Previous Pump Model on Clinical Outcomes.
Ann Thorac Surg Short Rep
September 2023
Advocate Heart Institute, Advocate Christ Medical Center, Oak Lawn, Illinois.
Background: We describe our clinical experience performing device exchange from a HeartMate II (HM2) or HVAD to a HeartMate 3 (HM3) left ventricular assist device.
Methods: A single-center retrospective study was performed of all patients (N = 14) who underwent a left ventricular assist device exchange from HM2 (n = 7) or HVAD (n = 7) to HM3 between October 2018 and October 2021. The primary outcome was 1-year overall survival, and secondary outcomes included adverse events through discharge.
Prothrombin Complex Concentrate vs Factor VII for Refractory Bleeding in Cardiac Surgery.
Ann Thorac Surg Short Rep
December 2023
Department of Cardiothoracic Surgery, OhioHealth Grant Medical Center, Columbus, Ohio.
Background: Perioperative bleeding remains an important complication of cardiac surgery. Current guidelines support goal-directed use of coagulation factor concentrates in refractory bleeding, but the optimal strategy is unclear. Four-factor prothrombin complex concentrate (4F-PCC) has theoretical advantages over recombinant activated factor VII (rFVIIa) because of expanded mechanistic targets and lower rates of adverse events, but comparative data are limited.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!